Is The Beauty Health Co. overvalued or undervalued?
As of May 10, 2023, The Beauty Health Co. is considered overvalued and risky, with poor financial metrics such as a Price to Book Value of 4.38 and negative ROCE and ROE ratios, despite a year-to-date return of 49.06% that underperformed the S&P 500's 12.22%.
As of 10 May 2023, the valuation grade for The Beauty Health Co. moved from attractive to risky, indicating a shift towards a more negative outlook. The company is currently overvalued, as evidenced by its Price to Book Value of 4.38 and negative ratios such as EV to EBIT at -6.16 and EV to EBITDA at -12.23. These metrics suggest significant financial distress, particularly highlighted by a ROCE of -27.18% and an ROE of -94.21%.In comparison to its peers, The Beauty Health Co. has a less favorable EV to EBITDA ratio than Paragon 28, Inc. at -52.8268 and SI-BONE, Inc. at -25.8938, both of which also reflect risky valuations. Despite a strong year-to-date return of 49.06%, the company has underperformed the S&P 500 over the same period, which returned 12.22%. This stark contrast in performance underscores the challenges facing The Beauty Health Co. and reinforces its current overvaluation status.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
